Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome

Basit Öğe Kaydı
dc.contributor.authorKaratay, Eylem
dc.contributor.authorUtku, Ozlem Gul
dc.date.accessioned2020-06-25T18:34:55Z
dc.date.available2020-06-25T18:34:55Z
dc.date.issued2020
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground/Aims: The objective of this study is to determine the role of circulating resolvin D1 (RvD1) in patients with constipation subtype of irritable bowel syndrome (IBS-C) and evaluate the relationship between abdominal pain severity and RvD1 levels. Materials and Methods: This research included 55 patients with IBS-C and 36 healthy controls. Controls were selected from patients who applied to our department with similar complaints as IBS but were not diagnosed with any type of pathology after further investigations. All participants underwent complete blood count, C-reactive protein (CRP), and RvD1 levels measurements. We also recorded abdominal pain severity and the number of bowel movements. Patients with IBS-C were compared with respect to the demographic features and laboratory measurements. Results: The median CRP concentration in patients with IBS-C was significantly higher than that of controls (p=0.003). However, the median RvD1 concentration was significantly lower in the IBS group than that of the control group (p<0.001). The receiver operating characteristic curve analyses revealed that RvD1 concentration lower than 0.47 ng/mL and CRP concentration higher than 3.40 mg/L may identify patients with IBS-C with a high specificity. In the IBS group, there was a strong negative correlation between abdominal pain severity and RvD1 concentration (r=-0.766, p=0.001). Conclusion: This research demonstrates that patients with IBS-C have higher CRP and lower RvD1 concentrations than healthy controls. Both RvD1 and CRP concentrations predict the presence of IBS-C. Additionally, RvD1 concentrations decreased with the increase in abdominal pain severity. Further research works are needed for investigating the role of the RvD1 analogs in the treatment of IBS.en_US
dc.identifier.citationKaratay, E., & Gül, Ö. (2020). Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome. Turk J Gastroenterol, 31(2), 113–119.en_US
dc.identifier.doi10.5152/tjg.2020.19751
dc.identifier.endpage119en_US
dc.identifier.issn2148-5607
dc.identifier.issue2en_US
dc.identifier.pmid32141819
dc.identifier.scopus2-s2.0-85081529809
dc.identifier.scopusqualityQ3
dc.identifier.startpage113en_US
dc.identifier.trdizinid419858
dc.identifier.urihttps://doi.org/10.5152/tjg.2020.19751
dc.identifier.urihttps://hdl.handle.net/20.500.12587/8072
dc.identifier.volume31en_US
dc.identifier.wosWOS:000518828400005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal Of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIrritable bowel syndromeen_US
dc.subjectconstipationen_US
dc.subjectinflammationen_US
dc.subjectresolutionen_US
dc.subjectresolvin D1en_US
dc.titleSerum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndromeen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
tjg-31-2-113.pdf
Boyut:
349.07 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu